A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Trial Profile

A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Binimetinib (Primary) ; Imatinib
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2021.
    • 02 Jun 2015 Interim results for the phase I portion presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 The phase I portion has been completed in 18 patients and the phase II portion is underway, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top